Fracasos de la embolización en el tratamiento del mioma uterino / Embolization failures in the treatment of uterine myoma

La embolización de la arteria uterina ha sido descrita como un método efectivo y seguro en el tratamiento de los miomas sintomáticos. Se presentan 3 casos de pacientes con útero miomatoso sintomático, y su tratamiento mediante esta técnica. En estos 3 casos, las complicaciones postembolización de los miomas hizo necesaria la práctica de una histerectomía. Así mismo se describen otras complicaciones derivadas de la técnica señaladas en la revisión bibliográfica realizada

Uterine artery embolization has been described as an effective and safe treatment for women with symptomatic uterine leiomyomata. We report three cases of women with symptomatic myomatous uterus and their treatment by this approach. In these three cases, hysterectomy was required due to complications following the embolizations. We also describe other complications of this therapeutic approach that came to light in the literature review

Estudio inmunohistoquímico de los factores de trancripción de desarrollo neural (TTF1, ASCL1 y BRN2) en los tumores neuroendocrinos de próstata / Immunohistochemical study of the neural development transcription factors (TTF1, ASCL1 and BRN2) in neuroendocrine prostate tumours

Objetivo: El carcinoma neuroendocrino de célula pequeña de próstata es una neoplasia infrecuente que supone el 0,5-1% de todas las neoplasias prostáticas. La mediana de supervivencia cáncer-específica de los pacientes con carcinoma neuroendocrino de célula pequeña de próstata es de 19 meses, y el 60,5% de los pacientes presentan enfermedad metastásica. Los factores de transcripción de desarrollo neural son moléculas implicadas en la organogénesis del sistema nervioso central y de precursores neuroendocrinos de diversos tejidos, que incluyen la glándula suprarrenal, el tiroides, el pulmón y la próstata, entre otros órganos. Material y métodos: Presentamos 3 casos de esta infrecuente entidad, aplicando los nuevos criterios de la OMS. Realizamos estudios mediante tinción de H-E y analizamos la expresión de los factores de transcripción de desarrollo neurales Achaete-scute homolog like 1, Thyroid transcription factor 1 y los factores de transcripción clase iii/iv POU, como nueva línea de investigación en la carcinogénesis de los tumores neuroendocrinos de próstata. Resultados: En el caso 1 no se observó inmunoexpresión para TTF1. Los casos 2 y 3 presentaron inmunotinción positiva para ASCL1, e inmunotinción negativa en el caso 1. La inmunotinción para BRN2 fue negativa en el caso 1 y positiva en los casos 2 y 3. Conclusión: Actualmente, la OMS no reconoce ningún marcador molecular ni genético con valor pronóstico. ASCL-1 está relacionado con las vías de señalización NOTCH y WNT. ASCL-1, TTF1 y BRN2 podrían usarse para el diagnóstico precoz y como factor pronóstico y diana terapéutica

Objective: Prostatic small-cell neuroendocrine carcinoma is an uncommon malignancy that constitutes 0.5-1% of all prostate malignancies. The median cancer-specific survival of patients with prostatic small-cell neuroendocrine carcinoma is 19 months, and 60.5% of the patients have metastatic disease. Neural development transcription factors are molecules involved in the organogenesis of the central nervous system and of neuroendocrine precursors of various tissues, including the suprarenal gland, thyroid glands, lungs and prostate. Material and methods: We present 3 cases of this uncommon condition, applying the new World Health Organisation criteria. We conducted studies through haematoxylin and eosin staining and analysed the expression of the neural development transcription factors achaete-scute homolog like 1, thyroid transcription factor 1 and the class III/IV POU transcription factors, as a new research line in the carcinogenesis of prostatic neuroendocrine tumours. Results: In case 1, there was no TTF1 immunoexpression. Cases 2 and 3 had positive immunostaining for ASCL1, and Case 1 had negative immunostaining. BRN2 immunostaining was negative in case 1 and positive in cases 2 and 3. Conclusion: The World Health Organisation does not recognise any molecular or genetic marker with prognostic value. ASCL-1 is related to the NOTCH and WNT signalling pathways. ASCL-1, TTF1 and BRN2 could be used for early diagnosis and as prognostic factors and therapeutic targets

Immunohistochemical study of the neural development transcription factors (TTF1, ASCL1 and BRN2) in neuroendocrine prostate tumours. / Estudio inmunohistoquímico de los factores de trancripción de desarrollo neural (TTF1, ASCL1 y BRN2) en los tumores neuroendocrinos de próstata.

OBJECTIVE: Prostatic small-cell neuroendocrine carcinoma is an uncommon malignancy that constitutes 0.5-1% of all prostate malignancies. The median cancer-specific survival of patients with prostatic small-cell neuroendocrine carcinoma is 19 months, and 60.5% of the patients have metastatic disease. Neural development transcription factors are molecules involved in the organogenesis of the central nervous system and of neuroendocrine precursors of various tissues, including the suprarenal gland, thyroid glands, lungs and prostate. MATERIAL AND METHODS: We present 3 cases of this uncommon condition, applying the new World Health Organisation criteria. We conducted studies through haematoxylin and eosin staining and analysed the expression of the neural development transcription factors achaete-scute homolog like 1, thyroid transcription factor 1 and the class III/IV POU transcription factors, as a new research line in the carcinogenesis of prostatic neuroendocrine tumours. RESULTS: In case 1, there was no TTF1 immunoexpression. Cases 2 and 3 had positive immunostaining for ASCL1, and Case 1 had negative immunostaining. BRN2 immunostaining was negative in case 1 and positive in cases 2 and 3. CONCLUSION: The World Health Organisation does not recognise any molecular or genetic marker with prognostic value. ASCL-1 is related to the NOTCH and WNT signalling pathways. ASCL-1, TTF1 and BRN2 could be used for early diagnosis and as prognostic factors and therapeutic targets.

Teratoma ovárico maduro e inmaduro, a propósito de un caso / About a case of mature and immature ovarian teratoma

Resumen: CASO CLÍNICO: paciente de 30 años de edad, con diagnóstico de teratoma inmaduro, con deseos de preservar la fertilidad. Se indicó tratamiento quirúrgico conservador y quimioterapia coadyuvante, previa vitrificación de ovocitos. Un año después de finalizar la quimioterapia logró embarazarse mediante fecundación in vitro, realizada con sus propios óvulos desvitrificados. Después de tres años de la intervención quirúrgica se detectó otro quiste en el ovario contralateral, que se intervino y diagnosticó como teratoma maduro. CONCLUSIONES: el teratoma ovárico inmaduro es una neoplasia poco frecuente cuyo tratamiento aún se discute. Puesto que la mayoría de las pacientes son jóvenes debe intentarse la preservación de la fertilidad proponiéndoles la preservación de ovocitos. Debido a la alta tasa de recurrencia del tumor, casi siempre en forma de teratoma maduro, es importante el seguimiento estrecho después de finalizar el tratamiento.

Abstract: CLINICAL CASE: We present a peculiar case in which an immature teratoma is diagnosed by an ovarian torsion in a 30 year old patient. She wanted to preserve her fertility, so she underwent conservative surgical treatment, previous vitrification of her oocytes. One year after the end of the chemotherapeutic treatment, the patient became pregnant through in vitro fertilization performed with her own devitrified oocytes. Another cyst in the contralateral ovary was diagnosed three years after the surgical intervention so she was reintervenated, it was a mature teratoma. CONCLUSIONS: Immature ovarian teratoma is an uncommon pathology whose treatment is controversial. Since most patients are young, we should try to preserve fertility if the patient wishes, by offering cryopreservation of oocytes when indicated. Due to the high rate of recurrence, often in the form of mature teratoma, it is important to follow-up closely after the treatment.

El nefroma quístico. Presentación de dos casos y revisión de la literatura / Cystic nephroma. Report of two cases and bibliographic review

OBJETIVO: El nefroma quístico, quiste multilocular o nefroma multilocular quístico, es una neoplasia renal infrecuente, de comportamiento benigno que se descubre habitualmente de formal incidental. MÉTODO: Entre 2010 y 2015, 2 pacientes fueron diagnosticados en nuestro servicio de nefroma quístico. Se revisaron las historias clínicas de dichos pacientes y realizamos una revisión de la literatura sobre las lesiones quísticas renales tanto benignas como malignas. RESULTADO: En este trabajo presentamos dos nuevos casos correspondientes a dos mujeres de 75 y 33 años que fueron intervenidas con sospecha de neoplasia renal. CONCLUSIONES: El tratamiento de elección del nefroma quístico es la cirugía y el diagnóstico final es anatomopatológico. En el manejo de estas lesiones, es preciso hacer el diagnóstico diferencial con neoplasias renales malignas como el carcinoma renal quístico multilocular y el nefroblastoma quístico

OBJECTIVE: Multicystic nephroma (multilocular cystic nephroma, multilocular cyst) is a relatively rare benign neoplasm of the kidney. Most patients are asymptomatic and tumours are usually discovered incidentally. METHODS: Between 2010 and 2015, 2 patients with cystic nephroma at our institution were diagnosed and treated. Our study includes two new cases of cystic nephroma and a review of the literature about the differential diagnosis of a cystic renal mass. RESULTS: In this report we present two cases of multilocular cystic nephroma in a 75-year-old-female and a 33-year-old female. They were diagnosed clinically as a renal mass and surgery was performed. CONCLUSIONS: Surgery is the main treatment for cystic nephroma. The combination of clinical, biochemical and radiological features may help in lesion characterization but only histology can provide the definite diagnosis. The differential diagnosis includes multilocular cystic renal cell carcinoma and cystic nephroblastoma

[Cystic nephroma. Report of two cases and bibliographic review.] / El nefroma quístico. Presentación de dos casos y revisión de la literatura.

OBJECTIVE: Multicystic nephroma (multilocular cystic nephroma, multilocular cyst) is a relatively rare benign neoplasm of the kidney. Most patients are asymptomatic and tumours are usually discovered incidentally. METHODS: Between 2010 and 2015, 2 patients with cystic nephroma at our institution were diagnosed and treated. Our study includes two new cases of cystic nephroma and a review of the literature about the differential diagnosis of a cystic renal mass. RESULTS: In this report we present two cases of multilocular cystic nephroma in a 75-year-old-female and a 33-year-old female. They were diagnosed clinically as a renal mass and surgery was performed. CONCLUSIONS: Surgery is the main treatment for cystic nephroma. The combination of clinical, biochemical and radiological features may help in lesion characterization, but only histology can provide the definite diagnosis. The differential diagnosis includes multilocular cystic renal cell carcinoma and cystic nephroblastoma.

[Gatrointestinal stromal tumor: a case report]. / Tumor del estroma gastrointestinal: reporte de un caso.

Gastrointestinal stromal tumors are the most common mesenquimal neoplasms of the gastrointestinal tract. A preoperative diagnose of GIST it is very difficult to make, but up to 5% of the cases initially appear as a pelvic mass. Clinical case: 45-year-old patient attended in medical service by unspecific pain in the lower abdomen of several weeks of evolution. The abdominopelvic tomography evidence collection of 9×8 cm above of the uterus and sigma's right with air in the cavity, it is was compatible with pelvic abscess. Due to increased pain, we realized emergency exploratory laparotomy, which showed a 14 cm tumor, dependent of the small intestine, without ascites or involvement other organs of the digestive or reproductive tract. The excision of the tumor was successfully (non intraoperative rupture). The pathological study reported a bowel piece of 20 cm, in which a tumor of 14 cm with large central cavitation was identified. Histologically showed diffuse growth pattern and neoplastic epithelioid cells with low rate of mitosis (mitosis 1-2/5 mm2). The immunohistochemistry test reports strong expression of DOG-1 and focal expression in CD117 (c-kit), with very low proliferation index (Ki67). The molecular pathology study identified a mutation in exon 11, codon 557-558, the c-kit gene in the p.W557_K558del position. We use imatinib (400 mg/24 h) from the second month after surgery. Today keep in treatment, and clinical and laboratories following every month: in addition, to CT scans scheduled every 6 months.